Soligenix Begins Patient Enrollment for Phase 3 Study of Drug Candidate for Cutaneous T-Cell Lymphoma
Soligenix Begins Patient Enrollment for Phase 3 Study of Drug Candidate for Cutaneous T-Cell Lymphoma
Soligenix開始爲皮膚T細胞淋巴瘤藥物候選者的第三階段研究招募患者。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。